Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Brain Injuries, Concussion, Mild, Concussion, Brain, Near Point Convergence, Concussion, Intermediate
Interventions: BrainScope Ahead 300iP-O, SCAT5, Near Point Convergence; Device · Diagnostic Test
Lead sponsor: BrainScope Company, Inc.; Industry
Eligibility: 13 Years to 50 Years
Enrollment: 1,318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Storrs, Connecticut • Miami, Florida + 3 more

Conditions: Age-Related Macular Degeneration
Interventions: Palomid 529; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
Interventions: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 25,236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 156
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more

Conditions: Sensorineural Hearing Loss, Bilateral
Interventions: AAVAnc80-hOTOF via Akouos Delivery Device, AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism; Combination Product
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions: Stool Collection Kit; Device
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 27
States / cities: Dothan, Alabama • La Jolla, California • Mission Hills, California + 24 more

Conditions: Pancreatic Cancer
Interventions: Early detection pancreatic cancer test, Early detection pancreatic cancer test and MRI Imaging; Device
Lead sponsor: ClearNote Health; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
Interventions: nedosiran; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: Up to 11 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 7 more

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Untreated Adult Acute Myeloid Leukemia, Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: filgrastim, clofarabine, cytarabine; Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: Duarte, California • Stanford, California • Seattle, Washington

Conditions: Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Autism
Interventions: Yoga, dance and Mindful Movement; Other
Lead sponsor: USC Glorya Kaufman School of Dance; Other
Eligibility: 18 Years to 36 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-smoker, ADHD
Interventions: Nicotine nasal spray, Placebo; Drug
Lead sponsor: Scott Kollins, PhD; Other
Eligibility: 18 Years to 25 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: HFA-152A propellant, HFA-134A propellant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Marlton, New Jersey • Huntersville, North Carolina • San Antonio, Texas

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more

Conditions: Major Depression
Interventions: Interpersonal Psychotherapy, Problem-Solving Therapy, Brief Supportive Psychotherapy; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 90 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis in Children
Interventions: Infant PFT, Lung Clearance Index, Passive tidal breathing; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 1 Month to 5 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions: Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 1,775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 10
States / cities: Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more

Conditions: Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 18 Months
Enrollment: 1,394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Teens-Connect, Planet D; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 11 Years to 14 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Lactation, Bone Diseases, Endocrine
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Secondary Hyperparathyroidism-Chronic Kidney Disease
Interventions: Doxercalciferol (GZ427397), Calcitriol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more

Conditions: Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8
Interventions: Genetic Testing; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Primary Snoring, Sleep Apnea
Interventions: Facial-Flex; Device
Lead sponsor: Facial Concepts, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: ADHD
Interventions: KP415 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Zevra Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more

Search by objective public record fields.

Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC

Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Dance, Yoga, And Mindful Movement Training For ASD

Nicotine, Non-Smokers With and Without ADHD, and Genetics Study

A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Interpersonal Therapy for Depression in Breast Cancer

Determinants of Early Cystic Fibrosis Lung Disease

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes

African-American Bone Metabolism and Lactation Study

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot

Study Will Test the Theory That Training With the Facial-Flex Exercise Device Will Improve Snoring in Patients

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD